We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+45.38%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$22.7B
AUM Growth
+$6.43B
Cap. Flow
-$298M
Cap. Flow %
-1.32%
Top 10 Hldgs %
85.22%
Holding
124
New
14
Increased
20
Reduced
17
Closed
10

Top Buys

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$116M
2
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$86.7M
3
ADCT icon
ADC Therapeutics
ADCT
+$64M
4
NVTA
Invitae Corporation
NVTA
+$48M
5
SYRE icon
Spyre Therapeutics
SYRE
+$20.3M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$416M
2
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$101M
3
TCDA
Tricida, Inc. Common Stock
TCDA
+$51.2M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$36.8M
5
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$23.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.74%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRNX icon
76
Crinetics Pharmaceuticals
CRNX
$8.88B
$5.57M 0.02%
317,857
+142,857
+82% +$2.44M
CBAY
77
DELISTED
Cymabay Therapeutics
CBAY
$5.32M 0.02%
+1,522,792
New +$4.39M
CHMA
78
DELISTED
Chiasma, Inc. Common Stock
CHMA
$5.09M 0.02%
+946,701
New +$5.21M
IFRX icon
79
InflaRx
IFRX
$245M
$4.86M 0.02%
1,058,555
-719,860
-40% -$4.67M
ABEO icon
80
Abeona Therapeutics
ABEO
$342M
$4.64M 0.02%
63,627
– –
EVFM
81
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$4.03M 0.02%
95,000
+53,580
+129% +$3.61M
CNST
82
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$4.01M 0.02%
133,333
– –
OVID icon
83
Ovid Therapeutics
OVID
$424M
$3.38M 0.01%
458,253
+388,782
+560% +$1.82M
KZR
84
DELISTED
Kezar Life Sciences
KZR
$3.11M 0.01%
+60,000
New +$3.03M
VKTX icon
85
Viking Therapeutics
VKTX
$3.86B
$3.06M 0.01%
425,000
– –
GMDA
86
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$3.05M 0.01%
+666,666
New +$3.06M
DRNA
87
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$3.03M 0.01%
119,335
+37,400
+46% +$806K
RCUS icon
88
Arcus Biosciences
RCUS
$3.3B
$3.01M 0.01%
121,534
– –
GBT
89
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.97M 0.01%
47,000
– –
ARAV
90
DELISTED
Aravive, Inc. Common Stock
ARAV
$2.84M 0.01%
244,055
-242,278
-50% -$2.87M
NTLA icon
91
Intellia Therapeutics
NTLA
$1.5B
$2.7M 0.01%
128,538
– –
LKFT
92
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$2.58M 0.01%
13,072
– –
XLRN
93
DELISTED
Acceleron Pharma
XLRN
$2.57M 0.01%
27,000
– –
DNLI icon
94
Denali Therapeutics
DNLI
$3.78B
$2.54M 0.01%
104,900
– –
NGM
95
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$2.46M 0.01%
124,400
-125,600
-50% -$2.4M
ORTX
96
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$2.43M 0.01%
40,570
– –
APLT
97
DELISTED
Applied Therapeutics
APLT
$2.38M 0.01%
65,934
– –
IMTX icon
98
Immatics
IMTX
$1.19B
$2.36M 0.01%
150,000
– –
CPRX
99
DELISTED
Catalyst Pharmaceutical
CPRX
$2.31M 0.01%
500,000
-560,714
-53% -$2.52M
MTEM
100
DELISTED
Molecular Templates, Inc.
MTEM
$2.18M 0.01%
10,548
-5,313
-33% -$1.23M
1 2 3
4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2020 Portfolio in Review

As of Q2 2020, Baker Bros. Advisors held 124 positions worth $22.7B, up 40% from $16.2B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Baker Bros. Advisors's Q2 2020 filing shows 14 new, 20 increased, 17 reduced and 10 closed positions. Its largest new stake was Forma Therapeutics Holdings, Inc. Common Stock: 2,000,000 shares worth $93M. The largest sale was Seagen Inc. Common Stock, an estimated $416M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q2 2020 buy was Forma Therapeutics Holdings, Inc. Common Stock: 2,000,000 shares worth $93M.
  • Baker Bros. Advisors added most to MyoKardia, Inc. Common Stock in Q2 2020, an estimated $116M increase.
  • Baker Bros. Advisors's biggest Q2 2020 reduction was Seagen Inc. Common Stock, cutting an estimated $416M.
  • Baker Bros. Advisors fully exited Ra Pharmaceuticals, Inc. Common Stock in Q2 2020, selling an estimated $101M.
  • Baker Bros. Advisors's ten largest holdings make up 85% of its $22.7B portfolio in Q2 2020.
  • Baker Bros. Advisors opened 14 new positions and closed 10 in Q2 2020.
  • Baker Bros. Advisors's portfolio value rose 40% quarter-over-quarter to $22.7B.

Based on Baker Bros. Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.